Shire Acquires Lumena Pharmaceuticals
Shire expands rare disease portfolio with acquisition of Lumena Pharmaceuticals.
Shire has acquired Lumena Pharmaceuticals, a biopharmaceutical company with rare disease pipeline assets, for $260 million.
According to the company, the acquisition of Lumena will expand Shire’s rare disease pipeline and provide future opportunities for Shire’s gastrointestinal business. Lumena Pharmaceuticals brings to Shire two new oral therapeutic compounds for hepatic diseases; LUM001, in Phase 2 with four potential orphan indications and LUM002, ready to enter Phase 2 later in 2014.
LUM001 and LUM002 are both inhibitors of the apical sodium-dependent bile acid transporter, which is primarily responsible for recycling bile acids from the intestine to the liver.
Shire does not expect the acquisition of Lumena to result in a change to its previously stated earnings guidance for 2014.
Source: Shire
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
PacBio Chosen as Tech Partner for Global Alzheimer’s Disease Research Project
April 23rd 2025The project, the North African Dementia Registry, will unite multiple entities for the purpose of developing a comprehensive dataset to advance the research community’s understanding of Alzheimer’s disease and other dementias in diverse populations.
